LLY Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of 31.72% compared to Eli Lilly & Co.'s net margin of 33.55%. Eli Lilly & Co.'s return on equity of 106.26% beat Amgen, Inc.'s return on equity of 95.55%.

Eli Lilly & Co. has a consensus price target of $1,098.04, signalling downside risk potential of -0.91%. On the other hand Amgen, Inc. has an analysts' consensus of $327.74 which suggests that it could fall by -4.07%. Given that Amgen, Inc. has more downside risk than Eli Lilly & Co., analysts believe Eli Lilly & Co. is more attractive than Amgen, Inc..

Eli Lilly & Co. has a beta of 0.348, which suggesting that the stock is 65.185% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.551%.

Eli Lilly & Co. has a quarterly dividend of $1.50 per share corresponding to a yield of 0.54%. Amgen, Inc. offers a yield of 2.79% to investors and pays a quarterly dividend of $2.38 per share. Eli Lilly & Co. pays 44.39% of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen, Inc.'s is not.

Eli Lilly & Co. quarterly revenues are $17.6B, which are larger than Amgen, Inc. quarterly revenues of $9.6B. Eli Lilly & Co.'s net income of $5.6B is higher than Amgen, Inc.'s net income of $3.2B. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 54.80x while Amgen, Inc.'s PE ratio is 26.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 17.00x versus 5.15x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 31.72% compared to Eli Lilly & Co.'s net margin of -19.69%. Eli Lilly & Co.'s return on equity of 106.26% beat Moderna, Inc.'s return on equity of -30.18%.

Eli Lilly & Co. has a consensus price target of $1,098.04, signalling downside risk potential of -0.91%. On the other hand Moderna, Inc. has an analysts' consensus of $36.90 which suggests that it could grow by 2.81%. Given that Moderna, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Moderna, Inc. is more attractive than Eli Lilly & Co..

Eli Lilly & Co. has a beta of 0.348, which suggesting that the stock is 65.185% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.

Eli Lilly & Co. has a quarterly dividend of $1.50 per share corresponding to a yield of 0.54%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly & Co. pays 44.39% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly & Co. quarterly revenues are $17.6B, which are larger than Moderna, Inc. quarterly revenues of $1B. Eli Lilly & Co.'s net income of $5.6B is higher than Moderna, Inc.'s net income of -$200M. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 54.80x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 17.00x versus 6.23x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 31.72% compared to Eli Lilly & Co.'s net margin of 38.89%. Eli Lilly & Co.'s return on equity of 106.26% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Eli Lilly & Co. has a consensus price target of $1,098.04, signalling downside risk potential of -0.91%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $804.96 which suggests that it could fall by -0.9%. Given that Eli Lilly & Co. has more downside risk than Regeneron Pharmaceuticals, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Eli Lilly & Co. has a beta of 0.348, which suggesting that the stock is 65.185% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Eli Lilly & Co. has a quarterly dividend of $1.50 per share corresponding to a yield of 0.54%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.43% to investors and pays a quarterly dividend of $0.88 per share. Eli Lilly & Co. pays 44.39% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly & Co. quarterly revenues are $17.6B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Eli Lilly & Co.'s net income of $5.6B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 54.80x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 17.00x versus 6.28x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of 31.72% compared to Eli Lilly & Co.'s net margin of --. Eli Lilly & Co.'s return on equity of 106.26% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Eli Lilly & Co. has a consensus price target of $1,098.04, signalling downside risk potential of -0.91%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 188.42%. Given that Viking Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Viking Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Eli Lilly & Co. has a beta of 0.348, which suggesting that the stock is 65.185% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.988%.

Eli Lilly & Co. has a quarterly dividend of $1.50 per share corresponding to a yield of 0.54%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly & Co. pays 44.39% of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly & Co. quarterly revenues are $17.6B, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Eli Lilly & Co.'s net income of $5.6B is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 54.80x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 17.00x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.